Pharmaceuticals & Biotech Swedish Community

A small Alzheimer’s drug developer could get a fresh look as it heads toward a key mid-stage study and presents at a major research meeting. The big question is whether early safety and immune signals for its lead program can translate into partner interest and a step up in market attention.Read more

In 2026, the story is no longer about how many companies Swedencare can buy, but how effectively it can scale its existing brands (ProDen PlaqueOff and NaturVet) into global Big Box retail and e-commerce The Pet Humanization Play Swedencare's narrative rests on three pillars: The Global Brand Portfolio: Moving from a single product company to a diversified pet health giant. The story is about cross-selling, taking a successful dental product from Sweden and putting it in 2,000 Walmart stores in the US The Channel Pivot: Swedencare is taking direct control of its destiny by moving Amazon sales inhouse and entering Big Box retail like Walmart, CVS etc.Read more

Oncolytics Biotech is pushing a new immune-based cancer treatment that’s showing encouraging early signs in some of the hardest-to-treat cancers, including pancreatic and certain digestive cancers. A recent green light from a German regulator and fresh conference results hint at momentum, but the big question is whether later trial readouts can hold up.Read more

Catalysts Most Immediate Catalyst (1–2 Years): Strong Oncology Portfolio Growth: AstraZeneca’s cancer drugs Tagrisso, Imfinzi, Enhertu, and Calquence continue gaining market share, driving double-digit revenue growth in oncology. Respiratory & Cardiovascular Expansion: New approvals and label expansions in Farxiga (diabetes/heart failure) and Tezspire (severe asthma) can drive meaningful sales upside.Read more

Egetis Therapeutics is building a rare-disease medicine that could move from a niche European rollout to a much larger U.S. launch, helped by regulators and growing awareness that more patients may be diagnosed. The key swing factors are whether approvals and reimbursement arrive on time and whether doctors find and treat enough patients to support meaningful growth.Read more

Swedish Orphan Biovitrum is pushing a wave of new rare-disease medicines toward market, while a key hemophilia treatment keeps gaining ground across major countries. The upside depends on smooth approvals, strong doctor and payer uptake, and whether heavy near-term spending pays off before competition and slower growth in older products bite.Read more

Devyser Diagnostics aims to grow by turning more transplant testing in the U.S. into everyday clinical use as reimbursement and approvals fall into place. At the same time, growing demand for prenatal and blood-typing tests across major labs could lift repeat kit sales, but the story depends on key regulatory decisions and a few large partners delivering as expected.Read more

Ascelia Pharma is trying to bring a new kind of liver scan drug to patients with serious kidney problems, as worries grow about today’s common MRI contrast agents. If approval and a hospital partner fall into place, the company could go from having no sales to building a second leg in rare cancer treatment—though setbacks or stronger rivals could change the story fast.Read more

Mendus is trying to make cancer treatments work better after patients first respond, with several ongoing studies in leukemia that could broaden who its therapy helps. The big question is whether the trial results and funding hold up long enough for the company to turn its science into real sales.Read more